A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass
Elliott Bennett-Guerrero, Hilary P. Grocott, Jerrold H. Levy, Kevin A. Stierer, Charles W. Hogue, Albert T. Cheung, Mark F. Newman, Alison A. Carter, Daniel P. Rossignol, Charles D. Collard
Research output: Contribution to journal › Article › peer-review
59Scopus
citations
Fingerprint
Dive into the research topics of 'A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass'. Together they form a unique fingerprint.